One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

In resource-limited settings, genomic assays for hormone receptor-positive, HER2-negative breast cancer aren't always ...

Cancer treatment is so much more exciting now than it was even 5 or 10 years ago, because not only are treatments so much better, but they're so much easier to take. The stage of cancer is one of the ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...